FBLG READ THE FULL FBLG RESEARCH REPORT Business Update Approval from HREC for Phase 1/2 Diabetic Foot Ulcer Trial In ...

The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute ...

Dr. Raza Bokhari, Executive Chairman & CEO of Medicus will deliver a company presentation as Medicus enters 2026 with multiple Phase 2 Catalysts across clinical, regulatory, and pipeline expansion ...

Brain aneurysms occupy a unique and somewhat paradoxical position in cerebrovascular disease. Although unruptured aneurysms ...

Introduction Each year, millions of people experience recurrent diverticulitis episodes. Elective sigmoid colon resection reduces the risk of recurrence, but The American Society of Colon and Rectal ...

The Tuskegee syphilis study stands as one of the greatest moral failures in American medical history, a reminder of what ...

Background Inflammatory bowel disease (IBD) patients in China exhibit critically low levels of physical activity, yet evidence for telemedicine-based aerobic exercise interventions remains scarce, ...

Nyrada shares have hit a new record high after the company received approval to go ahead with a clinical trial in heart ...

WCG, a global leader in providing solutions that measurably improve and accelerate clinical research, today announced the publication of its 2026 Trends and Insights Report. This annual analysis ...

Medicus Pharma Ltd. (Nasdaq: MDCX) is a precision guided biotech/life sciences company focused on accelerating the clinical development programs of novel and potentially disruptive therapeutics assets ...

The death of a young biathlete has refocused attention on hypoxic training masks, especially their cardiovascular effects, in ...

Objective Anxiety affects up to one-third of adults with asthma and is linked to poorer disease outcomes and reduced quality ...